U.S. Food and Drug Administration

“ Plaintiffs’ Motion for Preliminary Injunction (ECF No. 3) is GRANTED in part. Pursuant to Federal Rule of Civil Procedure 65 (a) , Defendants and their officers, agents, servants, employees, attorneys, and any person in active concert or participation, are PRELIMINARILY ENJOINED from: “altering the status quo and rights as it relates to the availability of Mifepristone under the current operative January 2023 Risk Evaluation and Mitigation Strategy under 21 U.S.C. § 355-1 in Plaintiff States.” No bond shall be required. ”

“ In connection with its mandate to promote health and reduce the risk of harm, the Food and Drug Administration routinely makes decisions about whether and how products may be marketed in the United States. ”

“ Becerra, 1:17-493-JAO-RT (D. Haw.) , application holders, and healthcare providers and researchers. Id. at 10–11.
On December 16, 2021, FDA announced its conclusions regarding the Mifepristone REMS Program. ECF No. 51-5. On January 3, 2023, FDA accepted these conclusions by approving the supplemental applications proposing conforming modifications. ECF Nos. 51-8; 51-11. The 2023 REMS removed the in-person dispensing requirement and added a pharmacy-certification requirement. ECF Nos. 51-4, 51-5. The FDA maintained the Prescriber and Patient Agreement Form requirements. Id. ”

“ In addition, mammography user fees authorized by 42 U.S.C. 263b, export certification user fees authorized by 21 U.S.C. 381, and priority review user fees authorized by 21 U.S.C. 360n may be credited to this account, to remain available until expended. Buildings and Facilities For plans, construction, repair, improvement, extension, alteration, and purchase of fixed equipment or facilities of or used by the Food and Drug Administration, where not otherwise provided, $12,433,000, to remain available until expended. ”

“ There is, however, an FDA regulation that permits a manufacturer to make certain changes to its label before receiving the agency's approval. Among other things, this "changes being effected" (CBE) regulation provides that if a manufacturer is changing a label to "add or strengthen a contraindication, warning, precaution, or adverse reaction" or to "add or strengthen an instruction about dosage and administration that is intended to increase the safe use of the drug product," it may make the labeling change upon filing its supplemental application with the FDA ”

“ For the Food and Drug Administration to support improvements to the technological infrastructure for reporting and analysis of adverse events associated with the use of drugs and biological products, for each of fiscal years 2022 through 2031, $12,500,000.”. ”

“ Disclosure of other actions.—If at any time a tobacco product manufacturer eliminates or decreases an existing additive, or adds or increases an additive that has by regulation been designated by the Secretary as an additive that is not a human or animal carcinogen, or otherwise harmful to health under intended conditions of use, the manufacturer shall within 60 days of such action so advise the Secretary in writing. ”

“ The historical expansion of the statute's definition, furthermore, clearly points out Congress' intention of going beyond the medical usage. The 1906 Food and Drug Act, for instance, defined 'drug' in a rather limited way to include 'all medicines and preparations recognized in the United States Pharmacopoeia or National Formulary for internal or external use, and any substance or mixture of substances intended to be used for the cure, mitigation, or prevention of disease of either man or other animals.' 34 Stat. ”

“ Article 68
⁠The drug regulatory department under the State Council shall designate drug control institutions to test the following drugs before they are marketed or at the time they are imported. Drugs that are untested or fail testing shall not be marketed or imported ”

“ To amend the Federal Food, Drug, and Cosmetic Act to revise Aug. 14, 2008........ 3509 and extend the animal drug user fee program, to establish a program of fees relating to generic new animal drugs, to make certain technical corrections to the Food and Drug Administration Amendments Act of 2007, and for other purposes. ”

“ ANTIBIOTIC DRUGS SUBMITTED BEFORE NOVEMBER 21, 1997, BUT NOT APPROVED— `` (A) IN GENERAL— Notwithstanding any provision of the Food and Drug Administration Modernization Act of 1997 or any other provision of law, a sponsor of a drug that is the subject of an application described in subparagraph (B) (i) may elect to be eligible for, with respect to the drug— `` (i) (I) the 3-year exclusivity period referred to under clauses (iii) and (iv) of subsection (c) (3) (E) and under clauses (iii) and (iv) of subsection (j) (5) (F) , subject to the requirements of such clauses, as applicable ”

“ The only way to effectively protect the public health from the dangers of unsubstantiated modified risk tobacco products is to empower the Food and Drug Administration to require that products that tobacco manufacturers sold or distributed for risk reduction be reviewed in advance of marketing, and to require that the evidence relied on to support claims be fully verified. ”

“ If the Food and Drug Administration has carryover balances for the process for the review of abbreviated applications for generic new animal drugs in excess of 3 months of such operating reserves, then this adjustment shall not be made. If this adjustment is necessary, then the rationale for the amount of the increase shall be contained in the annual notice setting fees for fiscal year 2018. ”

“ The purpose of administrative exhaustion is to prevent “premature interference with agency processes, so that the agency may function efficiently and so that it may have an opportunity to correct its own errors, to afford the parties and the courts the benefit of its experience and expertise, and to compile a record which is adequate for judicial review.” ”

“ The issue, of course, is the safety and efficacy of products which Americans buy. The FDA has been given the responsibility and has executed that responsibility extraordinarily well to make sure when an American citizen buys a pharmaceutical product or a medication, it is what it says it is and it does what the doctor prescribes. ”

“ Article 50
⁠Staff members of MAHs, drug manufacturers, drug distributors, and medical institutions who are in direct contact with drugs shall undergo annual health checkups. No one who suffers from infectious diseases or any other diseases which may contaminate drugs may engage in any work involving direct contact with drugs. ”

“ The necessity for a standard becomes evident when it is remembered that acetyl­salicylic acid is not yet an official drug, and its purity, therefore, is not subject to the control of the federal Food and Drugs Act. It is worth while at this time to remind physicians that several brands of acetyl­salicylic acid (aspirin) have been found to comply with the standards set by the Council on Pharmacy and Chemistry and have been admitted to New and Non­official Remedies.261 These, of course, are thereby subject to the control of the federal law to conform to the standard to which they profess. ”

“ They also serve a distinct compensatory function that may motivate injured persons to come forward with information. Failure-to-warn actions, in particular, lend force to the FDCA's premise that manufacturers, not the FDA, bear primary responsibility for their drug labeling at all times. Thus, the FDA long maintained that state law offers an additional, and important, layer of consumer protection that complements FDA regulation. [12] The agency's 2006 preamble represents a dramatic change in position. ”

“ The pharmacist has felt his hampered position for some time, but now that the Pure Food and Drugs Act has become effective, we are face to face with the issue. With the United States Pharmacopœia and the National Formulary as the legal standards he will now be held responsible for the identity and quality of the drugs which he sells. ”

“ Requests to dispense incompatible or over-dosage prescriptions and prescriptions may be dispensed only after the prescribing physician makes corrections or re-signs the order.
⁠Drug distributors shall indicate the origin of the Chinese medicinal materials to be sold.
⁠Legally qualified pharmacists or other pharmaceutical professionals shall be responsible for the drug management, prescription examination and dispensing, and guidance of rational use of drugs. ”

“ Additional special rule.—Beginning 2 years after the date of enactment of the Family Smoking Prevention and Tobacco Control Act, a tobacco product manufacturer shall not use tobacco, including foreign grown tobacco, that contains a pesticide chemical residue that is at a level greater than is specified by any tolerance applicable under Federal law to domestically grown tobacco. ”

“ SAFETY LABELING CHANGES.— " (i) IN GENERAL.—In the case of a determination by the Secretary that a change in the labeling of a drug, class of drugs, or combination of drugs subject to this section is reasonably expected to mitigate a significant or unreasonable risk of a serious adverse event associated with use of the drug, the Secretary may— " (I) make reasonable efforts to notify informally, not later than 48 hours before the issuance of the interim final order, the sponsors of drugs who have a listing in effect under section 510 (j) for such drug or combination of drugs; " ”